CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma

Clinical Cancer Research

Volumn 9, Issue 8, 2003, Pages 3105-3114

  Weigel, Brenda J ^a,e   Rodeberg, David A ^b   Krieg, Arthur M ^c,d   Blazar, Bruce R ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d PFIZER INC   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL DNA; CPG 2006; CYCLOPHOSPHAMIDE; IMMUNOSTIMULATING AGENT; OLIGODEOXYNUCLEOTIDE DERIVATIVE; TOPOTECAN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DENDRITIC CELL; DNA SEQUENCE; DRUG EFFECT; DRUG POTENTIATION; FEMALE; IMMUNE RESPONSE; MALE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POSTOPERATIVE CARE; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CPG ISLANDS; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; OLIGONUCLEOTIDES; RHABDOMYOSARCOMA, EMBRYONAL; T-LYMPHOCYTES; TIME FACTORS; TOPOTECAN;

EID: 0042024964     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Pappo, A. S., Shapiro, D. N., and Crist, W. M. Rhabdomyosarcoma. Biology and treatment. Pediatr. Clin. North Am., 44: 953-972, 1997.
2. Crist, W. M., Anderson, J. R., Meza, J. L., Fryer, C., Raney, R. B., Ruymann, F. B., Breneman, J., Qualman, S. J., Wiener, E., Wharam, M., Lobe, T., Webber, B., Maurer, H. M., and Donaldson, S. S. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol., 19: 3091-3102, 2001.
3. Pappo, A., Anderson, J. R., Crist, W. M., Wharam, M. D., Breitfeld, P. P., Hawkins, D. R., Raney, R. B., Womer, R. B., Parham, D. N., Qualman, S. J., and Grier, H. E. Survival after relapse in children and adolescents with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study Group. J. Clin. Oncol., 17: 3487-3493, 1999.
4. Dranoff, G., Jaffe, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V., Hanada, H., Pardoll, D., and Mulligan, R. C. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA, 90: 3539-3543, 1993.
5. Chen, K., Braun, S., Lyman, S., Fan, Y., Traycoff, C. M., Wiebke, E. A., Gaddy, J., Sledge, G., Broxmeyer, H. E., and Cornetta, K. Anti-tumor activity and immunotherapeutic properties of Flt3-Ligand in a murine breast cancer model. Cancer Res., 57: 3511-3516, 1997.
6. Shimizu, K., Fields, R. C., Gieldlin, M., and Mule, J. J. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA, 96: 2268-2273, 1999.
7. Fallarino, F., Uyttenhove, C., Boon, T., and Gajewski, T. F. Improved efficacy of dendritic cell vaccines and successful immunization with tumor antigen peptide-pulsed peripheral blood mononuclear cells by coadministration of recombinant murine interleukin-12. Int. J. Cancer, 80: 324-333, 1999.
8. Krieg, A. M. An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. J. Lab. Clin. Med., 128: 128-133, 1996.
9. Sparwasser, T., Koch, E. S., Vabillus, R. M. Heeg, K., Lipford, G. B., Ellwart, J. W., and Wagner, H. Bacterial DNA and immunostimulatory CpG oligonucleotides trigger maturation and activation of murine dendritic cells. Eur. J. Immunol., 28: 2045-2054, 1998.
10. Hartmann, G., Weiner, G., and Krieg, A. M. CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. Proc. Natl. Acad. Sci. USA, 96: 9305-9310, 1999.
11. Hartmann, G., Weeranta, R. D., Ballas, Z. K., Payette, P., Blackwell, S., Suparto, I., Rasmussen, W. L., Waldschmidt, M., Sajuthi, D., Purcell, R. H., Davis, H. L., and Krieg, A. M. Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo. J. Immunol., 164: 1616-1624, 2000.
12. Klinman, D. M., Yi, A. K., Beaucage, S. L., Conaver, J., and Krieg, A. M. CpG motifs present in bacterial DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon γ. Proc. Natl. Acad. Sci. USA, 93: 2879-2883, 1996.
13. Jakob, T., Walker, P. S., Krieg, A. M., von Stebut, E., Udey, M. C., and Vogel, J. R. Bacterial DNA and CpG-containing oligodeoxynucleotides activate cutaneous dendritic cells and induce IL-12 production: implications for the augmentation Th1 responses. Int. Arch. Allergy Immunol., 118: 457-461, 1999.
14. Blazar, B. R., Krieg, A. M., and Taylor, P. A. Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naïve and bone marrow transplant (BMT) recipients. Blood, 98: 1217-1225, 2001.
15. Wooldridge, J. E., Ballas, Z., Krieg, A. M., and Weiner, G. J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood, 89: 2994-2998, 1997.
16. Carpentier, A. F., Chen, L., Maltenti, F., and Delattre, J. Y. Oligodeoxynucleotides containing CpG motifs can induce rejection of a neuroblastoma in mice. Cancer Res., 59: 5429-5432, 1999.
17. Carpentier, F., Xie, J., Mokhtari, K., and Delattre, J. Y. Successful treatment of intracranial gliomas in rat by oligodeoxynucleotides containing CpG motifs. Clin. Cancer Res., 6: 2469-2473, 2000.
18. Ballas, Z. K., Krieg, A. M., Warren, T., Rasmussen, W., Davis, H. L., Waldschmidt, M., and Weiner, G. Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J. Immunol., 167: 4878-4886, 2001.
19. + T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides. J. Immunol., 167: 5247-5253, 2001.
20. Proietti, E., Greco, G., Garrene, B., Baccarini, S., Mauri, C., Venditti, M., Carlei, D., and Belandelli, F. Importance of cyclophosphamide-induced bystander effect on T cell for a successful tumor eradication responses to adoptive immunotherapy in mice. J. Clin. Invest., 101: 429-441, 1998.
21. Evans, R., and Duffy, T. The immunological basis of tumor rejection: the absolute dependence of the effector arm on sensitized T cells after chemoimmunotherapy of a murine sarcoma. J. Immunol., 134: 4255-4260, 1985.
22. Evans, R. Combination therapy by using cyclophosphamide and tumor-sensitized lymphocytes: a possible mechanism of action. J. Immunol., 130: 2511-2513, 1983.
23. Pappo, A. S., Lyden, E., Breneman, J., Wiener, E., Teot, L., Meza, J., Crist, W., and Vietti, T. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: an intergroup rhabdomyosarcoma study. J. Clin. Oncol., 19: 213-219, 2001.
24. Sands, H., Gorey-Feret, L. J., Cocuzza, A. J., Hobbs, F. W., Chidester, D., and Trainor, G. L. Biodistribution and metabolism of internally 3H-labeled oligonucleotides. Mol. Pharmacol., 45: 932-943, 1994.
25. Weiner, G. J. Liu, H. M., Wooldridge, J. E., Dahl, C. E., and Krieg, A. M. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc. Natl. Acad. Sci. USA, 94: 10833-10837, 1997.
26. Wooldridge, J. E., Ballas, Z., Krieg, A. M., and Weiner, G. J. Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. Blood, 89: 2994-2998, 1997.
27. Liu, H. M., Newbrough, S. E., Bhatia, S. K., Dahle, C. E., Krieg, A. M., and Weiner, G. J. Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. Blood, 92: 3730-3736, 1998.
28. Davila, E., and Celis, E. Repeated administration of cytosine-phosphorothiolated guanine-containing oligonucleotides together with peptide/protein immunization results in enhanced CTL responses with anti-tumor activity. J. Immunol., 165: 539-547, 2000.
29. Chu, R. S., Targoni, O. S., Krieg, A. M., Lehmann, P. V., and Harding, C. V. CpG oligodeoxynucleotides acts as adjuvants that switch on T helper 1 (Th1) immunity. J. Exp. Med., 186: 1623-1631, 1997.
30. Cho, H. J., Takabayashi, K., Cheng, P. M., Nguyen, M. D., Corr, M., Tuck, S., and Raz, E. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Nat. Biotechnol., 18: 509-514, 2000.
31. Warren, T. L., Bhatia, S. K., Acosta, A. M., Dahle, C. E., Ratliff, T. L., Krieg, A. M., and Weiner, G. J. APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J. Immunol., 165: 6244-6251, 2000.
32. Brunner, C., Seiderer, J., and Schlamp, A. Enhanced dendritic cell maturation by TNF-α or cytidine-phosphate-guanosine DNA drives T cell activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol., 165: 6278-6286, 2000.
33. Mackall, C. J. T-cell immunodeficiency following cytotoxic antineoplastic therapy: a review. Oncologist, 4: 370-378, 1999.
34. Krieg, A. M., Love-Homan, L., Yi, A. K., and Harty, J. T. CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. J. Immunol., 161: 2428-2434, 1998.
35. Ballas, Z. K., Rasmussen, W. L., and Krieg, A. M. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. J. Immunol., 157: 840-1845, 1996.
36. Cowdery, J. S., Chace, J. H., Yi, A. K., and Krieg, A. M. Bacterial DNA induces NK cells to produce IFN-γ in vivo and increases the toxicity of lipopolysaccharides. J. Immunol., 156: 4570-4575, 1996.
37. Kreig, A. M. The role of CpG motifs in innate immunity. Curr. Opin. Immunol., 12: 35-43, 2000.
38. Auf, G., Carpentier, A. F., Chen, L., Le Clanche, C., and Delattre, J. Y. Implication of macrophages in tumor rejection induced by CpG-oligodeoxynucleotides without antigen. Clin. Cancer Res., 7: 3540-3543, 2001.
39. + T cells. Curr. Opin. Immunol., 13: 465-470, 2001.
40. Soloski, M. J. Recognition of tumor cells by the innate immune system. Curr. Opin. Immunol., 13: 154-162, 2001.
41. + T cells. Nat. Immunol., 2: 430-435, 2001.
42. Speiser, D. E., Pittet, M. J., Valmori, D., Dunbar, R., Rimoldi, D., Lienard, D., MacDonald, H. R., Cerottini, J. C., Cerundolo, V., and Romero, P. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med., 190: 775-782, 1999.
43. + immunoregulatory cells. J. Immunol., 167: 1137-1140, 2001.
44. Shimizu, J., Yamazaki, S., and Sakaguchi, S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol., 163: 5211-5218, 1999.
45. Carpentier, A. F., Auf G., and Delattre, J-Y. CpG-oligodeoxynucleotides for cancer immunotherapy: review of the literature and potential applications in malignant glioma. Front. Biosci., 8: e115-e127, 2003.